arrow
A

Ali Gürbüz

Necmettin Erbakan University
H指数:4
被引数:74

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score

CLIP-M评分在进展期黏膜黑色素瘤中的开发与内部验证:探索性预后分层及与RMH评分的比较评估

2026-05-220
OAAI
Does the Duration of FLOT Infusion Change the Outcome of Perioperative Treatment for Gastric Cancer? Comparing 24-and 48-h Infusions

氟嘧啶、奥沙利铂和曲氟尿苷替加氟方案输注持续时间是否影响胃癌围手术期治疗结局?比较24小时与48小时输注

2026-05-190
PRE
Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study

免疫检查点抑制剂在错配修复缺陷型结直肠癌患者中的疗效、安全性和生存结局:一项回顾性、多中心研究

2026-02-270
OAAI
Survival outcomes and recurrence patterns of early-stage HER2-positive breast cancer patients on adjuvant T-DM1 treatment: Turkish Oncology Group (TOG) Study

早期HER2阳性乳腺癌患者接受辅助T-DM1治疗的生存结局与复发模式:土耳其肿瘤学组(TOG)研究

2025-12-010
PRE
Prognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways

激素敏感性前列腺癌患者接受新型雄激素受体抑制剂治疗后前列腺特异性抗原KELIM评分的预后效应:开创新途径

2025-11-010
OA
Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

预后营养指数作为转移性激素敏感型前列腺癌的生物标志物:对生存期和治疗优化的影响

2025-02-190
OAAI